Bilberry supplementation in type 2 diabetes
| ISRCTN | ISRCTN14907666 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN14907666 |
| Sponsors | Aarhus University, Aarhus University Hospital |
| Funders | Plantefonden, Ekhagastiftelsen |
- Submission date
- 12/08/2026
- Registration date
- 21/08/2026
- Last edited
- 21/08/2026
- Recruitment status
- Recruiting
- Overall study status
- Ongoing
- Condition category
- Nutritional, Metabolic, Endocrine
Plain English summary of protocol
Background and study aims
Type 2 diabetes (T2D) is a major global health challenge and is associated with an increased risk of cardiovascular (heart) disease and other serious complications. Diet is an important component of T2D management. Lab and animal studies suggest that bilberries and bilberry-derived anthocyanins may influence pathways related to lipid and glucose metabolism, insulin sensitivity and oxidative stress. Findings from human studies also indicate potential effects on inflammatory markers, blood lipids and oxidised LDL (oxLDL). However, evidence from clinical trials in people with T2D remains limited. The aim of this study is to investigate the effects of 12 weeks of dietary supplementation with bilberries in individuals with T2D.
Who can participate?
Patients aged 18 years and over with type 2 diabetes
What does the study involve?
Participants will be randomised to receive either a bilberry drink or a control drink for 12 weeks. Participants will consume 500 ml of the study drink daily throughout the 12-week intervention. Participants will attend two study visits, one before and one after the 12-week intervention. Each visit will last about 4 hours and will include:
1. Fasting blood samples and collection of urine and faecal samples
2. Measurements of blood pressure, pulse, weight, height and body composition
3. Questionnaires on health, diet and physical activity
4. Assessment of physical function, including handgrip strength, a 6-minute walk test and a sit-to-stand test
5. Continuous glucose monitoring using a sensor placed on the upper arm
6. An optional mixed-meal test to assess the glucose response
7. An optional eye examination to assess the small blood vessels of the retina, including optical coherence tomography (OCT)
Participants will continue their usual diabetes treatment throughout the study
What are the possible benefits and risks of participating?
The bilberry and control drinks are not expected to pose any significant risks. Participants with a known allergy or intolerance to gluten, bilberries or legumes will not be eligible to participate.
Blood samples are collected using standard blood sampling procedures. There may be minor and temporary discomfort, bruising or swelling at the sampling site.
Where is the study run from?
Steno Diabetes Center Aarhus (Denmark)
When is the study starting and how long is it expected to run for?
June 2026 to February 2028
Who is funding the study?
1. Plantefonden (Denmark)
2. Ekhagastiftelsen (Denmark)
Who is the main contact?
Signe Kaas Ovesen, sko@clin.au.dk
Contact information
Principal investigator
Palle Juul Jensen Blvd 11
Aarhus N
8200
Denmark
| 0000-0002-1953-8631 | |
| Phone | +45 (0)30134245 |
| soeren.gregersen@aarhus.rm.dk |
Scientific, Public
Palle Juul Jensen Blvd 11
Aarhus N
8200
Denmark
| Phone | +45 (0)60846988 |
|---|---|
| sko@clin.au.dk |
Study information
| Primary study design | Interventional |
|---|---|
| Allocation | Randomized controlled trial |
| Masking | Blinded (masking used) |
| Control | Placebo |
| Assignment | Parallel |
| Purpose | Treatment |
| Scientific title | Bilberry supplementation in type 2 diabetes: effects on cardiometabolic health, exercise capacity and inflammation (DiaBerry): a randomized, double-blind, placebo-controlled trial |
| Study acronym | DiaBerry |
| Study objectives | The aim of the study is to investigate the effects of 12 weeks of dietary supplementation with Vaccinium myrtillus (bilberries) in individuals with type 2 diabetes (T2D). Outcomes related to systemic inflammation, glycaemic regulation and cardiovascular health will be assessed at baseline and after a 12-week intervention period. |
| Ethics approval(s) |
Approved 25/03/2026, The Scientific Ethics Committees for the Central Denmark Region (Skottenborg 26, Viborg, 8800, Denmark; +45 (0)7841 0183; komite@rm.dk), ref: 1-10-72-18-26 |
| Health condition(s) or problem(s) studied | Cardiometabolic health, exercise capacity and inflammation in individuals with type 2 diabetes |
| Intervention | Individuals who meet all inclusion criteria and none of the exclusion criteria will, after providing both oral and written informed consent to participate in the project, be randomised according to a computer generated random sequence. Block randomisation will be performed in a 1:1 ratio to the respective intervention. Both study participants and research staff involved in the project will be blinded to treatment allocation. Arm 1: Dietary Intervention: Bilberry beverage. Participants randomized to this group will be instructed to daily consume 500 ml of bilberry beverage for 12 weeks (± 7 days). The beverage contains naturally occurring bioactive compounds derived from bilberries, including polyphenols such as anthocyanins. Both the bilberry and control beverages are isocaloric and matched for taste, appearance, and mouth feel. Participants are instructed to consume the beverage daily as part of their usual routines, with the total daily intake divided into at least two doses (250 ml in the morning and 250 ml in the evening). Compliance will be assessed using two complementary methods. Participants will be asked to return any unopened beverages at the follow-up visit, with the number of unopened cartons subtracted from the total amount provided to estimate actual intake. Compliance will also be evaluated objectively by quantifying anthocyanin-derived metabolites in faecal samples collected at follow-up Arm 2: Placebo comparator: Control beverage. Participants randomized to this group will be instructed to daily consume 500 ml of the control beverage for 12 weeks (± 7 days). The control beverage does not contain bilberry-derived bioactive compounds but is isocaloric and matched to the bilberry beverage for taste, appearance, and mouth feel. Participants are instructed to consume the beverage daily as part of their usual routines, with the total daily intake divided into at least two doses (250 ml in the morning and 250 ml in the evening). Compliance will be assessed by asking participants to return any unopened beverages at the follow-up visit, with the number of unopened cartons subtracted from the total number provided to estimate actual intake. |
| Intervention type | Supplement |
| Primary outcome measure(s) |
|
| Key secondary outcome measure(s) |
|
| Completion date | 28/02/2028 |
Eligibility
| Participant type(s) | |
|---|---|
| Age group | Mixed |
| Lower age limit | 18 Years |
| Upper age limit | 99 Years |
| Sex | All |
| Target sample size at registration | 120 |
| Key inclusion criteria | 1. Diagnosed type 2 diabetes mellitus 2. Age ≥18 years 3. Written informed consent for participation |
| Key exclusion criteria | 1. Age ≥18 years 2. Daily intake of blueberries >15 g 3. Allergy or intolerance to gluten, bilberries or legumes 4. Previous randomisation in the DiaBerry study 5. Unable to provide informed consent 6. Treatment with immunosuppressive medications, including prednisolone 7. Planned initiation or modification of antidiabetic treatment during the period from 12 weeks before intervention start until completion of the intervention 8. Planned initiation or modification of lipid-lowering or cholesterol-lowering treatment during the period from 4 weeks before intervention start until completion of the intervention 9. Severe somatic or psychiatric disease rendering the participant unsuitable for participation, as assessed by the investigators |
| Date of first enrolment | 08/06/2026 |
| Date of final enrolment | 31/12/2027 |
Locations
Countries of recruitment
- Denmark
Study participating centre
Aarhus N
8200
Denmark
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|
Editorial Notes
21/08/2026: Study's existence confirmed by the Scientific Ethics Committees for the Central Denmark Region.